Follow up to February 2014 Harman Law Post: FDA Requires Label Change Citing Increased Blood Clot Risk with Testosterone Products
On June 19, 2014 the FDA announced they are requiring manufacturers of testosterone therapy products (“TT”) to add blood clot warnings to the drug labeling. The testosterone products include:
- Axiron
- AndroDerm
- AndroGel (the biggest seller and creator of the marketing term “LowT”)
- Delatestryl
- Fortesta
- Striant
- Testim
- Testopel
See the February 2014 Harman Law post on testosterone therapy: Testosterone Therapy Rx Linked to Increased Risk of Heart Attack, Stroke and Potentially Fatal Conditions
Harman Law is representing men who have experienced heart attacks, strokes or blood clots after taking testosterone therapy as well as men who develop prostate cancer after long-term “TT.”
Posted on behalf of
